Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PLoS neglected tropical diseases 2018-11, Vol.12 (11), p.e0006837
Hauptverfasser:	Olliaro, Piero L, Kuesel, Annette C, Halleux, Christine M, Sullivan, Mark, Reeder, John C
Format:	Artikel
Sprache:	eng
Schlagworte:	Actors Animals Aquatic insects Blindness Care and treatment Chemotherapy Diagnosis Disease Diseases Drug approval Drug Approval - legislation & jurisprudence Drug Approval - organization & administration Drug development Drug dosages Drugs FDA approval Filaricides - pharmacology Financial institutions Financing Food Global health Humans Incentives Infections Medical sciences Medicine Medicine and Health Sciences Neglected Diseases - drug therapy Neglected Diseases - parasitology New products Nonprofit organizations Onchocerca - drug effects Onchocerca - physiology Onchocerciasis Onchocerciasis, Ocular - drug therapy Organizations Pharmaceutical industry Philanthropy Poverty Profits Public finance R&D Registration Research & development Research and analysis methods Return on investment Returns Reviews Rivers Skin Social Sciences Training Tropical climate Tropical diseases United States United States Food and Drug Administration Vaccines Viewpoints
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!